Arcoxia Advisory Committee Will Be Missing Key Participants From 2005 COX-2 Meeting
This article was originally published in The Pink Sheet Daily
Executive Summary
Many of the key panelists during the 2005 advisory committee review of COX-2 inhibitor cardiovascular safety will not be participating in the Arthritis Advisory Committee's April 12 review of Merck's Vioxx follow-on Arcoxia